Infliximab-induced lupus-like syndrome associated with autoimmune hepatitis

Inflammatory Bowel Diseases

Volumn 14, Issue 5, 2008, Pages 723-725

  Marques, M ^a   Magro, F ^a,b   Cardoso, H ^a,b   Carneiro, F ^a,c   Portugal, R ^a   Lopes, J ^a   Costa Santos, C ^a  

^a HOSPITAL DE SÃO JOÃO   (Portugal)

^b University of Porto   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; MESALAZINE; PREDNISOLONE;

ABDOMINAL PAIN; ADULT; AUTOIMMUNE HEPATITIS; CASE REPORT; CHRONIC HEPATITIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; LETTER; LIVER BIOPSY; LUPUS LIKE SYNDROME; PRIORITY JOURNAL; STEROID THERAPY; ULCERATIVE COLITIS;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOPSY; COLITIS, ULCERATIVE; DIAGNOSIS, DIFFERENTIAL; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER; LUPUS VULGARIS; SYNDROME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 44349107627     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20293     Document Type: Letter

References (12)

1. Minner PB Jr. Factors influencing the relapse of patients with inflammatory bowel disease. Am J Gastroenterol. 1997;92:1S-4S.
2. Uetrecht J. Current trends in drug-induced autoimmunity. Autoimmun Rev. 2005;4:309-314.
3. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929-938.
4. Sarzi-Puttini P, Ardizzone S, Manzionna G, et al. Infliximab-induced lupus in Crohn's disease: a case report. Dig Liver Dis. 2003;35:814-817.
5. Rubin RL. Drug-induced lupus. Toxicology. 2005;209:135-147.
6. Debandt M, Vittecoq O, Descamps V, et al. Anti-TNF-α-induced systemic lupus syndrome. Clin Rheumatol. 2003;22:56-61.
7. Assche VG, Vermeire S, Rutgeerts P. Safety issues with biological therapies for inflammatory bowel disease. Curr Opin Gastroenterol. 2007;1:15-21
8. Colombel JF, Loftus EV, Tremaine WJ, et al. The safety of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology. 2004;126:19-31.
9. Vasoo S. Drug-induced lupus: an update. Lupus. 2006;15:757-761.
10. Saleem G, Li SC, MacPherson BR, et al. Hepatitis with interface inflammation and IgG, IgM, and IgA anti-double stranded DNA antibodies following infliximab therapy: comment on article by Charles et al. Arthritis Rheum. 2001;44:1966-1968.
11. Tobon GJ, Canãs C, Jaller JJ, et al. Serious liver disease induced by infliximab. Clin Rheumatol. 2007;26:578-581.
12. Germano V, Picchianti Diamanti A, Baccano G, et al. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis. 2005;64:1519-1520.